A Phase 4 interventional study of valacyclovir hydrochloride in Herpes Genitalis, sponsored by GlaxoSmithKline. Terminated at 5 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-24.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing valacyclovir in Herpes Genitalis — none open to participants now, none under way, none of them phase 3. Valacyclovir · Herpes Genitalis.
Among the 14 studies testing valacyclovir in Herpes Genitalis, this one is the 11th largest by enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2004, is one of 6 in phase 4, and was the 5th registered.
70 studies on the registry are indexed under Herpes Genitalis; 3 are open to participants now.
Browse Herpes Genitalis studies →None of the 14 studies testing valacyclovir in Herpes Genitalis is open now. The open studies under Herpes Genitalis, anywhere →
Valacyclovir: first FDA approval 1995 (VALTREX). What it is approved for, and how studies give it, is on its page →
Of the 1 Herpes Genitalis study recruiting now, none set no upper age limit and 1 stops at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 3 started in 2004.
This study's enrollment of 7 is below the median of 103 across 51 interventional studies indexed under Herpes Genitalis.
Median enrollment 50 across the 11 interventional studies. Of the 13 that completed or were terminated, 5 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 14 have an industry lead sponsor. The 6 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
11 studies in Herpes Genitalis by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 10 finished, 4 (40%) have results posted.
Among the 11 studies in Herpes Genitalis by GlaxoSmithKline, this one is one of 2 that started in 2004, is one of 4 in phase 4, and was the 5th registered.
GlaxoSmithKline’s Herpes Genitalis studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing valacyclovir in Herpes Genitalis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 11 in Herpes Genitalis:
This tab as a report to print or save as PDF → With an account.
This clinical research study will be an international trial evaluating the safety and effectiveness of a marketed drug compared to placebo (like a sugar pill) for the suppression of repeated genital herpes infections in HIV-infected subjects with CD4+ count \<100 cells/mm3.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Valaciclovir (VAL) 500mg twice daily for 6 months, and episodic treatment with VAL 1000mg twice daily for 5 days or 10 days, when required for treatment of a genital herpes recurrence.
Drug: valacyclovir hydrochloride
Matching placebo twice daily for 6 months, and episodic treatment with VAL 1000mg twice daily for 5 or 10 days, when required for treatment of a genital herpes recurrence.
Drug: valacyclovir hydrochloride
valacyclovir hydrochloride
Adverse Events
The nature and incidence of adverse events, by treatment group, reported during the 6-month study will be summarized.
Time frame: Up to 6 months
Proportion of recurrence of genital HSV
Secondary outcome measures are the proportion of subjects recurrence-free of genital HSV at 6 months, and the time to first culture-positive recurrence of genital HSV.
Time frame: Up to 6 months
Time to first culture-positive recurrence of genital HSV
Secondary outcome measures are the proportion of subjects recurrence-free of genital HSV at 6 months, and the time to first culture-positive recurrence of genital HSV.
Time frame: Up to 6 months
Ran from Mar 2004 to primary completion in Oct 2004, 7 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Valacyclovir